Emapalumab study for MDA5-related lung disease
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Lungs & breathing, Skin clinical trials.
This trial tests if emapalumab can help people with a serious lung condition linked to MDA5 antibodies. It may be an option for those with worsening breathing despite other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung disease that is getting worse, shown by tests like CT scans or breathing tests.
- You have MDA5 antibodies in your blood.
- Your ferritin levels are higher than normal.
- You are at least 18 years old.
- You do not have a current untreated infection, active shingles, or need ECMO life support.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
This trial tests a treatment called 3T therapy for people with MDA5-positive dermatomyositis, a rare autoimmune disease that affects the skin, muscles, and often the lungs. The goal is to see if 3T therapy can help control the disease and improve lung function.
This trial tests an investigational drug called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rashes. The goal is to see if the drug can help control the disease.
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
This study tests whether a new drug called teclistamab can help people with a rare, aggressive lung disease caused by MDA5 antibodies. The disease hasn't improved after standard treatments, and this trial is looking for people who need urgent help with breathing.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.